Pembrolizumab: all 1,753 studies that test it

Page 9 of 18. Open to participants first (418), then studies with results posted, then the rest; newest registration first within each.

• Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin LymphomaCompletedNCT03035331Phase 1/2Results posted
• A Study Of Pembrolizumab In Combination With Trastuzumab-DM1CompletedNCT03032107Phase 1Results posted
• Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT03029598Phase 1/2Results posted
• Trial to Evaluate Efficacy and Safety of Pembrolizumab and Gemcitabine in HER2-negative ABCCompletedNCT03025880Phase 2Results posted
• Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast CancerCompletedNCT03025035Phase 2Results posted
• Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)TerminatedNCT03019588Phase 3Results posted
• Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast CancerCompletedNCT03018080Phase 2Results posted
• A Trial of Pembrolizumab for Refractory Atypical and Anaplastic MeningiomaTerminatedNCT03016091Phase 2Results posted
• Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)CompletedNCT03010176Phase 1Results posted
• Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADTCompletedNCT03007732Phase 2Results posted
• A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular CarcinomaCompletedNCT03006926Phase 1Results posted
• Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid TumorsCompletedNCT03006887Phase 1Results posted
• SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLCCompletedNCT03004183Phase 2Results posted
• A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) BlockadeCompletedNCT03003676Phase 1Results posted
• Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017CompletedNCT03003468Phase 1/2Results posted
• A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast CancerCompletedNCT02999477Phase 1Results posted
• Study of Pembrolizumab in Locally Advanced Esophageal AdenocarcinomaActive, not recruitingNCT02998268Phase 2Results posted
• Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid LeukemiaCompletedNCT02996474Phase 1/2Results posted
• PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural MesotheliomaCompletedNCT02991482Phase 3Results posted
• HDCRT Plus Pembrolizumab in Advanced MalignanciesCompletedNCT02987166Phase 1Results posted
• Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-IntronTerminatedNCT02982720Phase 2Results posted
• Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell TransplantationCompletedNCT02981914Early Phase 1Results posted
• Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal CancerCompletedNCT02981524Phase 2Results posted
• Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast CancerCompletedNCT02981303Phase 2Results posted
• Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)CompletedNCT02973997Phase 2Results posted
• Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013)TerminatedNCT02972034Phase 1Results posted
• Pembrolizumab in Refractory Advanced Esophageal CancerCompletedNCT02971956Phase 2Results posted
• Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast CancerCompletedNCT02971761Phase 2Results posted
• Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to ChemotherapyActive, not recruitingNCT02971748Phase 2Results posted
• Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV MelanomaActive, not recruitingNCT02965716Phase 2Results posted
• Pembrolizumab in Patients With Locally Advanced or Metastatic Skin CancerCompletedNCT02964559Phase 2Results posted
• Interleukin-2 and Pembrolizumab for Metastatic Kidney CancerCompletedNCT02964078Phase 2Results posted
• Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001)CompletedNCT02964013Phase 1Results posted
• Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung CancerTerminatedNCT02963610Phase 1/2Results posted
• Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung CancerCompletedNCT02955758Phase 2Results posted
• Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) CancerCompletedNCT02954536Phase 2Results posted
• Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic MutationsTerminatedNCT02949843Phase 2Results posted
• Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by SurgeryActive, not recruitingNCT02949219Phase 2Results posted
• A Study of Pembrolizumab in Patients With Neuroendocrine TumorsCompletedNCT02939651Phase 2Results posted
• Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating AgentsCompletedNCT02936752Phase 1Results posted
• Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)TerminatedNCT02934503Phase 2Results posted
• Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal CancerTerminatedNCT02933944Phase 1Results posted
• Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal CancerCompletedNCT02921256Phase 2Results posted
• Pembrolizumab in Metastatic Anal CancerCompletedNCT02919969Phase 2Results posted
• Perioperative Chemo and Pembrolizumab in Gastric CancerCompletedNCT02918162Phase 2Results posted
• Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic CancerCompletedNCT02907099Phase 2Results posted
• Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)TerminatedNCT02906332Phase 2Results posted
• JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid TumorsCompletedNCT02904226Phase 1/2Results posted
• Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT02901899Phase 2Results posted
• Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian CancerTerminatedNCT02900560Phase 2Results posted
• Pembrolizumab in Ultramutated and Hypermutated Endometrial CancerCompletedNCT02899793Phase 2Results posted
• Pembrolizumab in HNSCC With Residual Disease After RadiationTerminatedNCT02892201Phase 2Results posted
• Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by SurgeryCompletedNCT02888665Phase 1/2Results posted
• Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial NeoplasiaCompletedNCT02882282Phase 2Results posted
• A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid TumorsTerminatedNCT02880371Phase 1/2Results posted
• Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell TransplantCompletedNCT02880228Phase 2Results posted
• Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung CancerCompletedNCT02879994Phase 2Results posted
• Pembrolizumab in Advanced/Metastatic Acral Lentiginous MelanomaCompletedNCT02875132Phase 2Results posted
• Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin LymphomaTerminatedNCT02875067Phase 1/2Results posted
• Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal CancerCompletedNCT02865811Phase 2Results posted
• Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033)CompletedNCT02864394Phase 3Results posted
• Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain MetastasesCompletedNCT02858869Phase 1Results posted
• Stereotactic Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) for Oligometastatic Renal TumoursCompletedNCT02855203Phase 1/2Results posted
• Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)CompletedNCT02853344Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)CompletedNCT02853331Phase 3Results posted
• Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT02853318Phase 2Results posted
• Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361)CompletedNCT02853305Phase 3Results posted
• A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive GlioblastomaActive, not recruitingNCT02852655Phase 1Results posted
• Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older PatientsCompletedNCT02845297Phase 2Results posted
• Preoperative Chemoradiotherapy and MK-3475 for Esophageal Squamous Cell Carcinoma (ACTS-29)CompletedNCT02844075Phase 2Results posted
• A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay StudyCompletedNCT02841748Phase 2Results posted
• PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal CancerCompletedNCT02837263Phase 1Results posted
• Trial of Pembrolizumab for Advanced Penile Squamous Cell CarcinomaTerminatedNCT02837042Phase 2Results posted
• Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab (MK-3475) in Chinese Participants With Non-Small-Cell Lung Cancer (MK-3475-032/KEYNOTE-032)CompletedNCT02835690Phase 1Results posted
• Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).TerminatedNCT02834975Phase 2Results posted
• Pembrolizumab + Poly-ICLC in MRP Colon CancerCompletedNCT02834052Phase 1/2Results posted
• Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction CancerCompletedNCT02830594Phase 2Results posted
• Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151)CompletedNCT02821000Phase 1Results posted
• PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and NeckTerminatedNCT02819752Phase 1Results posted
• Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)CompletedNCT02819518Phase 3Results posted
• Neoadjuvant PembrolizumabCompletedNCT02818920Phase 2Results posted
• Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell CarcinomaActive, not recruitingNCT02811861Phase 3Results posted
• Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder CancerCompletedNCT02808143Phase 1Results posted
• A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid TumorsCompletedNCT02799095Phase 1/2Results posted
• Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199)CompletedNCT02787005Phase 2Results posted
• Pembrolizumab in Patients With Advanced Malignant Pleural MesotheliomaCompletedNCT02784171Phase 2/3Results posted
• Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast CancerActive, not recruitingNCT02778685Phase 2Results posted
• Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck CancerCompletedNCT02777385Phase 2Results posted
• A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)CompletedNCT02775435Phase 3Results posted
• Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for TransplantCompletedNCT02771197Phase 2Results posted
• High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AMLCompletedNCT02768792Phase 2Results posted
• Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast CancerCompletedNCT02768701Phase 2Results posted
• Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic LeukemiaTerminatedNCT02767934Phase 2Results posted
• Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary CancerCompletedNCT02766582Phase 2Results posted
• A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell CarcinomaCompletedNCT02759575Phase 1/2Results posted
• Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast CancerActive, not recruitingNCT02752685Phase 2Results posted
• A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)CompletedNCT02752074Phase 3Results posted
• Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV MelanomaTerminatedNCT02748564Phase 2Results posted
• Pembrolizumab and Ipilimumab After Prior Immunotherapy for MelanomaActive, not recruitingNCT02743819Phase 2Results posted
• Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography Texture Analysis as a Predictive BiomarkerTerminatedNCT02740920Phase 2Results posted

← Pembrolizumab overview